Global efforts to fight HIV are under growing pressure as major funding cuts threaten to slow progress at a critical moment in the global health response. New research and United Nations warnings suggest that reduced international aid could reverse years of progress in prevention and treatment programs worldwide.
The HIV Aid Cuts Crisis is now a central concern ahead of the United Nations High-Level Meeting on HIV, scheduled for June 22–23. Health experts and global leaders are warning that financial shortfalls could make it harder to meet international targets aimed at ending AIDS as a public health threat by 2030.
UN Secretary-General António Guterres recently said the world is not on track to meet the 2025 HIV targets set in a previous global agreement. These targets aim for 95% of people with HIV to know their status, 95% to receive treatment, and 95% of those on treatment to achieve viral suppression.
Despite progress in recent years, major gaps remain. At the end of 2024, an estimated 9.2 million people were still unable to access HIV treatment. There were around 630,000 AIDS-related deaths, nearly double the 2025 target level, and 1.3 million new HIV infections were recorded globally.
Experts warn that funding cuts are now threatening to slow or reverse these gains. International organizations such as the United States and the Global Fund have historically provided the majority of external HIV funding, particularly in low-income regions.
Recent projections suggest that US support for HIV programs could decline significantly in the coming years. Some estimates indicate reductions of between 42% and 97% in funding to certain recipient countries by 2030. These cuts are expected to affect programs across sub-Saharan Africa and parts of Asia.
A wide analysis of 29 countries found that combined funding from the US and the Global Fund could fall by about $4.3 billion by 2029. The study also suggests that US contributions may drop by 29%, while Global Fund support could decrease by 15% over the same period.
Countries such as Uganda, Mozambique, Nigeria, Malawi, and Senegal are expected to face some of the largest reductions in aid. In several cases, funding cuts may exceed 50%, raising concerns about how national health systems will maintain essential HIV services.
In many regions, external donors currently finance the majority of HIV treatment and prevention programs. In western and central Africa, around 90% of treatment funding comes from external sources, while prevention programs in sub-Saharan Africa rely on roughly 80% external support.
Health policy experts warn that domestic governments may struggle to absorb the financial burden created by shrinking international aid. In some cases, required co-financing commitments may even exceed projected national health budgets, creating additional strain on already limited resources.
Reports also show early signs of service disruption linked to funding declines. HIV testing has reportedly fallen by 12%, while fewer children are starting and continuing antiretroviral treatment. The number of people using preventive medication, known as pre-exposure prophylaxis or PrEP, has dropped by about 42%.
Experts say these declines could have long-term consequences for infection rates and treatment coverage if not addressed quickly. Reduced access to testing and prevention services increases the risk of new infections, especially in high-burden regions.
The closure of key US-led health initiatives and restructuring of global programs has also contributed to uncertainty. Short-term bridge funding has helped maintain some services, but at reduced levels compared to previous years.
Despite the financial challenges, health experts say there is still hope in new medical advances. One of the most promising developments is lenacapavir, a long-acting injectable drug that can prevent HIV transmission with just two doses per year.
Early rollout of lenacapavir has already begun, with tens of thousands of people receiving initial injections. Health officials say the treatment could become more widely available in the coming years, especially as production expands and costs fall.
Experts believe that if combined with stable funding and strong health systems, new prevention tools could significantly reduce global HIV infections. However, they warn that innovation alone will not be enough without sustained financial support.
The HIV Aid Cuts Crisis highlights a critical turning point in global health policy. While scientific progress continues to improve prevention and treatment options, shrinking financial support threatens to slow implementation on the ground.
As world leaders prepare to meet at the United Nations High-Level Meeting on HIV, the focus will be on how to close funding gaps and maintain momentum toward ending HIV as a global public health threat by 2030. The outcome of these discussions may determine whether current progress can be sustained or whether the world risks falling behind its long-term goals.
